학술논문
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
Document Type
article
Author
Joan Brunet; Josep Tabernero; Mieke Van Hemelrijck; Salvatore Grisanti; Bruno Vincenzi; Isabel Ruiz-Camps; Juan Aguilar-Company; Daniela Ferrante; Oriol Mirallas; Amanda Jackson; Beth Russell; Ramon Salazar; Aleix Prat; Daniele Generali; Nadia Harbeck; Alberto Zambelli; Carlo Alberto Tondini; David J Pinato; Lorenza Rimassa; Armando Santoro; Neha Chopra; Tom Newsom-Davis; Gino M Dettorre; Saoirse Dolly; Angela Loizidou; John Chester; Uma Mukherjee; Mark Bower; Christopher C T Sng; Alexia Bertuzzi; Ricard Mesia; Ailsa Sita-Lumsden; Elia Seguí; Federica Biello; Pavetha Seeva; Gianpiero Rizzo; Michela Libertini; Antonio Maconi; Charlotte Moss; Rossella Bertulli; Diego Ottaviani; Raquel Liñan; Andrea Marrari; M Carmen Carmona-García; Valeria Tovazzi; Vittoria Fotia; Claudia Andrea Cruz; Nadia Saoudi-Gonzalez; Eudald Felip; Ariadna Roqué; Alvin J X Lee; David García-Illescas; Roxana Reyes; Yien Ning Sophia Wong; Lorenza Scotti; Javier Marco-Hernández; Andrea Patriarca; Lorenzo Chiudinelli; Michela Franchi; Alessandra Gennari; Nikolaos Diamantis
Source
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Subject
Language
English
ISSN
2051-1426
Abstract
Background Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study.Methods In a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets.Results We evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p